New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) vs Enanta Pharmaceuticals, Inc. (ENTA)

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Enanta Pharmaceuticals, Inc. are both Biotechnology companies. Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Enanta Pharmaceuticals, Inc. are of similar size ($237.8M and $232.7M). Across the 1 metrics below, Enanta Pharmaceuticals, Inc. leads on 1 and Clinuvel Pharmaceuticals Ltd. - Sponsored ADR on 0.

Valuation

Metric CUVL ENTA Biotechnology median
P/E — n/m 8.49
P/S — 3.52 8.56
P/B — 2.19 2.04
Price to free cash flow — n/m 23.84
EV/EBITDA — n/m 0.69
EV/Sales — 0.43 8.00
Earnings yield — (30.94%) (35.81%)
Free cash flow yield — (19.29%) (25.41%)

Profitability

Metric CUVL ENTA Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (99.01%) 0.00%
Net margin — (108.33%) 0.00%
Free cash flow margin — (67.88%) 0.00%
Return on equity — (94.19%) (51.58%)
Return on assets — (24.54%) (45.91%)
Return on invested capital — 0.00% 0.00%

Growth

Metric CUVL ENTA Biotechnology median
Revenue growth (TTM) — (3.56%) 7.20%
EPS growth (last fiscal year) (2.13%) 38.72% 29.04%
Revenue growth, 5-year CAGR — (8.28%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CUVL ENTA Biotechnology median
Debt to equity — 0.00 0.00
Current ratio — 3.78 4.79
Net debt to EBITDA — 3.37 1.01

Dividend

Metric CUVL ENTA Biotechnology median
Dividend yield 0.62% — 0.41%
Payout ratio — — —

Size

Metric CUVL ENTA Biotechnology median
Market cap 237.81m 232.69m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack